Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Cardiac Arrest in Residential Areas With Mobile First-responder Activation

NCT04446585 · tracked via the Priya Life Science Denmark tracker
Sponsor
Emergency Medical Services, Capital Region, Denmark
Phase
Not applicable
Started
2021-12-01
Last updated
2023-09-15

Condition(s) studied

Out-Of-Hospital Cardiac Arrest

Investigational drug(s) / intervention(s)

Automated External Defibrillator (AED)Training in cardiopulmonary resuscitation and AED useActivation of citizen responders

Automated External Defibrillator (AED): Deployment of AEDs

Training in cardiopulmonary resuscitation and AED use: Residents will undergo 30-minute courses at study start and if needed during the trial period. During the course they will also be recruited as citizen responders

Activation of citizen responders: Citizen responders will be activated in case of suspected cardiac arrest through the heart runner app.

Study summary

The study aims to increase proportions of bystander defibrillation during out-of-hospital cardiac arrest (hereof referred to as cardiac arrest) in residential areas with a high density of cardiac arrests. The intervention consists of Automated External Defibrillators (AEDs) and residents' involvement in resuscitation through training and enrollment as citizen responders.

Eligibility

Sex
ALL
Min age
8 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All witnessed cardiac arrests recognized registered in the Danish Cardiac Arrest Registry occurring within the study sites. This excludes non witnessed cardiac arrests. * Witnessed cardiac arrest * Non-traumatic etiology, this excludes intoxication, drowning or suicide. Exclusion Criteria: * Cardiac arrest occurring in a nursing home * Cardiac arrest not treated by the EMS due to ethical reasons or obvious signs of death * Not true cardiac arrest (suspected, but not verified) * Cardiac arrests witnessed by the emergency medical personnel

Primary outcome measure(s)

  • Bystander defibrillation — Up to five years after implementation of the intervention
    Proportion of bystander defibrillation of witnessed cardiac arrests

Trial sites (1)

FacilityCityRegionStatus
Emergency Medical Services Copenhagen Ballerup Municipality The Capital Region Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04446585 on ClinicalTrials.gov ↗ ← All trials in Denmark